Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Protalix BioTherapeutics, Inc.

Market Cap 165M 0 143M 131M 123M 231M 15.7B 234M 1.55B 605M 7.64B 620M 607M 26.46B P/E Ratio 2026 *
10.7x
P/E Ratio 2027 * 41.8x
Enterprise Value 165M 0 143M 131M 123M 231M 15.7B 234M 1.55B 605M 7.64B 620M 607M 26.46B EV / Sales 2026 *
2.11x
EV / Sales 2027 * 2.44x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 30/06/2019
Director of Finance/CFO 58 24/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member 73 01/07/2008
Director/Board Member 82 01/11/2014
Director/Board Member 58 30/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+3.29% - - 165M
-2.41%+0.69%+40.12%+154.01% 1,035B
+1.07%+5.57%+55.14%+50.53% 574B
+1.32%+1.24%+18.92%+64.81% 397B
+0.77%+0.77%+21.19%+15.95% 324B
-0.85%-0.68%+23.44%+14.94% 281B
+0.44%+5.39%+25.86%+35.39% 278B
+1.66%+1.20%-44.41%-47.37% 193B
+0.32%+2.78%+21.72%+62.37% 191B
-0.22%-2.78%+14.90%+60.77% 156B
Average -0.13%+1.15%+19.65%+45.71% 381.1B
Weighted average by Cap. -0.74%+1.29%+28.93%+71.62%

Financials

2026 *2027 *
Net sales 78.3M 0 67.63M 62.32M 58.33M 109M 7.44B 111M 736M 287M 3.62B 294M 288M 12.54B 67.56M 0 58.36M 53.77M 50.34M 94.33M 6.42B 95.79M 635M 248M 3.13B 254M 248M 10.82B
Net income 15.72M 0 13.58M 12.51M 11.71M 21.95M 1.49B 22.29M 148M 57.61M 727M 59.01M 57.75M 2.52B 4.07M 0 3.52M 3.24M 3.03M 5.69M 387M 5.78M 38.28M 14.93M 188M 15.29M 14.96M 653M
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.090USD
Average target price
11.00USD
Spread / Average Target
+426.32%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!